Delivery Order SPE2DR25D1202-SPE2DR26F72MW
- Not listed
- The Defense Logistics Agency awarded a $2,173.01 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens. The contract, which is a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA, requires delivery by October 22, 2025, to the company's distribution facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. The contract is valued at $3,226.24 with a firm fixed price and an ultimate completion date of September 10, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was awarded competitively with no set-aside designation and represents a child...
- The Defense Logistics Agency awarded a $3,558.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $33,236.84 and is scheduled for completion by August 7, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,476.56 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL in pre-filled pen form on December 2, 2025, with completion scheduled for December 3, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $14,645.91 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on September 9, 2025, with completion targeted for September 10, 2025. This competitive award utilizes firm fixed pricing with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $11,906.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on November 17, 2025, with an ultimate completion date of November 18, 2025. This non-competitive delivery order was executed without a set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $54,899.82 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 15 mg/0.5 ml pen injections on November 25, 2025, with completion expected by November 26, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was awarded without...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pre-filled pens valued at $5,398.78. This is a firm fixed price delivery order with an ultimate completion date of December 9, 2025, issued under a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,537.40 on June 2, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F72MWDelivery Order
The Defense Logistics Agency awarded a $41,950.68 delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pre-filled pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 25, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies globally. This Zepbound delivery order demonstrates AmerisourceBergen's role in supplying specialized pharmaceutical products to support Defense Health Agency and other federal healthcare systems. AmerisourceBergen's extensive portfolio of federal contracts reflects its capability to compete successfully for medical supply requirements across multiple therapeutic domains. The company's performance under its DLA prime vendor contract positions it to fulfill urgent pharmaceutical needs for military medical programs, with the delivery order completion scheduled for November 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.0k | 11/23/25 |